BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17372204)

  • 1. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
    Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
    J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
    Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
    J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
    Vigna E; Naldini L; Tamagnone L; Longati P; Bardelli A; Maina F; Ponzetto C; Comoglio PM
    Cell Mol Biol (Noisy-le-grand); 1994 Jul; 40(5):597-604. PubMed ID: 7981617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
    Landgraf KE; Santell L; Billeci KL; Quan C; Young JC; Maun HR; Kirchhofer D; Lazarus RA
    J Biol Chem; 2010 Dec; 285(51):40362-72. PubMed ID: 20937841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
    J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP).
    Donate LE; Gherardi E; Srinivasan N; Sowdhamini R; Aparicio S; Blundell TL
    Protein Sci; 1994 Dec; 3(12):2378-94. PubMed ID: 7756992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of engineered recombinant hepatocyte growth factor cleaved and activated by Genenase I.
    Hayata D; Fukuta K; Matsumoto K; Adachi E; Hanada K; Adachi K; Nakamura T
    J Biotechnol; 2008 Feb; 133(4):478-85. PubMed ID: 18178280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
    Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
    Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
    FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: activation of pro-HGF.
    Mizuno K; Tanoue Y; Okano I; Harano T; Takada K; Nakamura T
    Biochem Biophys Res Commun; 1994 Feb; 198(3):1161-9. PubMed ID: 8117273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.